Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is regarded as a tightly linking oncogene in many types of cancer. However, the prognostic role of EZH2 in breast cancer (BC) still remains controversial. Our study aimed to evaluate the clinical and prognostic relevance of EZH2 in BC patients based on published studies. 11 studies totally containing 2330 patients (1052 EZH2-positive and 1278 EZH2-negative) were included in our meta-analysis. Our data showed that EZH2 over-expression was significantly associated with estrogen receptor (ER) negativity [OR=0.227, 95% CI=0.174-0.297, P=0.000], progesterone receptor (PR) negativity [OR=0.454, 95% CI=0.300-0.687, P=0.000], human epidermal growth factor receptor type 2 (HER-2) positivity [OR=1.846, 95% CI=1.366-2.496, P=0.000], invasive ductal cancer (IDC) [OR=2.237, 95% CI=1.489-3.361, P=0.000], race (Caucasian) [OR=0.707, 95% CI=0.522-0.957, P=0.025], high histological grade [OR=3.177, 95% CI=2.012-5.014, P=0.000] and triple-negative status (TNBCs) [OR=5.380, 95% CI=1.065-27.187, P=0.042], which led to a poor OS rate in BC [RR=2.193, 95% CI=1.495-3.217, P=0.000]. In conclusion, EZH2 participated in the progression of BC as a putative factor, and over-expression of EZH2 was distinctly correlated with a poor patient survival. EZH2 may serve as a prognostic biomarker and target in BC patients.
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xu
X
Wang
Department of General Surgery, Tengzhou Central People's Hospital, Tengzhou 277500, China.
Bo
B
Hu
Department of General Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan 215000, China.
Hugang
H
Shen
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Hao
H
Zhou
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xiaofeng
X
Xue
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yan
Y
Chen
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Shaoji
S
Chen
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Ye
Y
Han
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Bin
B
Yuan
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Hong
H
Zhao
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China. Electronic address: strexboy@163.com.
Qiaoming
Q
Zhi
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China. Electronic address: sdyt_kuang@163.com.
Yuting
Y
Kuang
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018450:Disease Progression; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D009367:Neoplasm Staging; D016017:Odds Ratio; D063151:Polycomb Repressive Complex 2 / Q000032:analysis*; D012307:Risk Factors; D016896:Treatment Outcome; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2
Breast cancer; EZH2; Meta-analysis; Overall survival; Prognosis